Teriparatide

  • CAS Number: 52232-67-4

Teriparatide is a recombinant human parathyroid hormone fragment for the treatment of osteoporosis. The most common use is the treatment of women in postmenopause with established osteoporosis and increased risk for fracture. The drug was approved in the U.S. under the brand name Forteo for Lilly Pharmaceuticals in November 2002 and in Germany in late 2003 as a trademark Forsteo. The active agent is produced by recombinant DNA technology.

In the U.S., currently in progress ( 2010) A clinical study on osteogenesis imperfecta.

This medicinal product must not be used in patients who suffer from other diseases of the bone, such as Paget's disease, bone cancer or bone metastases, radiation therapy of the skeleton were subjected, have hypercalcaemia or an unexplained increase of the enzyme alkaline phosphatase, or severe kidney disease suffer.

CAS registry number Anatomical Therapeutic Chemical Classification System DrugBank Paget's disease of bone Bone tumor Bone metastasis Digital Object Identifier
342838
de